The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tips for Diagnosing Metabolic Myopathies

Tips for Diagnosing Metabolic Myopathies

September 17, 2019 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
AJPhoto / Science Source

AJPhoto / Science Source

When evaluating patients with possible myopathic symptoms, rheumatologists must consider a rare, but important, group of inherited disorders: the metabolic myopathies. However, their diagnosis often remains a challenge. Early recognition of these primary metabolic myopathies is essential to help prevent disease morbidity and mortality from rhabdomyolysis. Here, we focus on the metabolic myopathies that present with primarily non-systemic issues and lead to exercise intolerance with dynamic myopathic symptoms.

You Might Also Like
  • Metabolic Myopathies
  • ACR 2013 State-of-the-Art Clinical Symposium: How to Identify Signs of Myositis and Metabolic Myopathies
  • 2015 ACR/ARHP Annual Meeting: How to Identify, Manage Metabolic Myopathies & Their Mimics
Explore This Issue
September 2019
Also By This Author
  • Study Elucidates Potential Flare Pathways in Rheumatoid Arthritis

Pathophysiology of Metabolic Myopathies

In cells, glucose and free fatty acids provide the main fuels used to produce adenosine triphosphate (ATP), the cell’s main source of energy. The process of glycogenolysis breaks down stored glycogen into a major source of usable
glucose. Through the processes of glycolysis, the Krebs cycle and, ultimately, the mitochondrial respiratory chain, the energy in glucose (4 kcal/g) and in free fatty acids (9 kcal/g) is liberated.1,2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A heterogeneous group of individually rare genetic disorders, metabolic myopathies are primary inborn errors of metabolism (IEM). These disorders impact one or more proteins involved in the intermediary metabolism of glucose and free fatty acids, and most of them reduce the adequate production of ATP. Many bodily systems can be affected by such deficits. However, because muscle tissue is so reliant on high amounts of ATP, especially during exercise, it is particularly susceptible to impact from ATP deficits.2-4

The metabolic myopathies are known for their diversity of phenotype and genotype. These enzyme defects can lead to a variety of presentations, depending on the exact gene affected and the severity of the mutation. More severe mutations tend to affect several organ systems and present in infancy or early childhood with such symptoms as liver disease, cardiomyopathy and encephalopathy. Some mutation types lead to progressive disease with persistent weakness, and sometimes cause additional non-myopathic symptoms as well.1-4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

However, some types of mutations lead to partial enzymatic function resulting in milder presentations. People with these types of mutations may have myo­pathic symptoms only, typically (though not always) non-fixed symptoms that occur in response to exercise or other metabolic stress. Such myopathies can prove challenging diagnostically, revealing exercise intolerance only without any other systemic abnormalities.1-4

Subtypes of Metabolic Myopathies

Metabolic myopathies are generally classified into three main subtypes: defects of glycogen metabolism, disorders of lipid metabolism, and mitochondrial disease.

Glycogen storage diseases

Dr. Tarnopolsky

Dr. Tarnopolsky

Impairments in glycogenolysis, glycogen production or of anaerobic glycolysis are often grouped together as the glycogen storage diseases (GSDs). If not enough ATP can be made available to cells via glycolysis and glycogenolysis during intense exercise, cramping and other such symptoms can result.4

Mark Tarnopolsky, MD, PhD, FRCPC, is a professor of pediatrics and medicine in the Division of Neuromuscular and Neurometabolic Disorders at McMaster University, Hamilton, Ontario. He explains that we use specific energy sources during different types of activity: “If you had to go up a flight of stairs or run to catch the bus, the muscle is utilizing mostly glucose or glycogen. If there is glycogen storage disease, then this energy can’t be delivered to the muscle.”

Around half of the more than 20 currently known GSDs manifest with myopathic disease. The most common disorder of glycogen metabolism is also the most common metabolic myopathy overall: McArdle’s disease (GSD-V), whose prevalence is approximately one in 40,000.5

In a minority of disorders, symptoms arise not from problems with the lack of availability of products used for cellular metabolism, but because of structural changes due to the disease process itself. For example, in Pompe disease (GSD-II), the pathology derives from a lysosomal defect that leads to glycogen buildup in the lysosomes. This eventually damages the muscles, resulting in a fixed, progressive myopathy.

Fatty acid oxidation defects

Disorders of fatty acid oxidation and oxidation transport are less common than those of glycogen metabolism. Milder cases of such disorders can also present in adulthood as myalgia and exercise intolerance.6 Of the 18 or so identified genetic defects known to cause disease, around half are thought to cause myopathic symptoms. Carnitine palmitoyltransferase II (CPT II) deficiency is the most common disorder in this group.5

“Longer duration and lower intensity activities rely more heavily on lipid metabolism. These activities can precipitate an energy crisis in a fatty acid oxidation defect [FAOD] or mitochondrial disease,” explains Dr. Tarnopolsky. “[Patients] may [have] symptoms if they went for a two-hour walk and forgot to eat beforehand, if they rented bikes and went for a three-hour bike ride, that sort of stress. Eventually we run out of glycogen in our muscles and start dipping into fat stores.” This starts symptoms in these patients.

Mitochondrial myopathies

Disorders of the mitochondrial chain represent the third group of metabolic myopathies, resulting from problems with the final common pathway for energy derivation. These will often present with similar triggers as FAODs. However, most mitochondrial diseases will cause additional non-myopathic symptoms, as well. Depending on the mutation and severity, these can include diabetes, seizures, hearing loss, stroke and a wide variety of possible neurological symptoms. About one in 8,000 people are affected.1,5

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions Tagged With: creatinine kinese, genetic disease, genetic disorders, Metabolic Myopathies, rhabdomyolysisIssue: September 2019

You Might Also Like:
  • Metabolic Myopathies
  • ACR 2013 State-of-the-Art Clinical Symposium: How to Identify Signs of Myositis and Metabolic Myopathies
  • 2015 ACR/ARHP Annual Meeting: How to Identify, Manage Metabolic Myopathies & Their Mimics
  • Myopathies

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.